Cencora (Cencora) ROCE % : 24.37% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Cencora ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cencora's annualized ROCE % for the quarter that ended in Dec. 2023 was 24.37%.

Cencora ROCE % Historical Data

The historical data trend for Cencora's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cencora ROCE % Chart

Cencora Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

ROCE %

Get a 7-Day Free Trial

11.60

-51.53

18.15

16.62

18.18

Cencora Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															19.96	17.42	19.29	14.81	24.37

Cencora ROCE % Calculation

Cencora's annualized ROCE % for the fiscal year that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	2436.486	/	( ( (56560.616 - 43477.955)	+	(62558.746 - 48831.198) )	/ 2 )
	=	2436.486	/	( (13082.661	+	13727.548)	/ 2 )
	=	2436.486	/	13405.1045
	=	18.18 %

Cencora's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	3368.056	/	( ( (62558.746 - 48831.198)	+	(64690.297 - 50773.472) )	/ 2 )
	=	3368.056	/	( ( 13727.548	+	13916.825 )	/ 2 )
	=	3368.056	/	13822.1865
	=	24.37 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Cencora (NYSE:COR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cencora ROCE % Related Terms

Thank you for viewing the detailed overview of Cencora's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cencora (Cencora) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cencora Inc (NYSE:COR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ABG:Germany C1CO34:Brazil ABC:Austria

Address

1 West First Avenue, Conshohocken, PA, USA, 19428-1800

Website

https://www.cencora.com

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the U.S. pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Executives

Leslie E Donato	officer: EVP & Chief Strategy Officer	227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Elizabeth S Campbell	officer: Executive Vice President	1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Steven H Collis	officer: President & CEO	1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Lazarus Krikorian	officer: Senior Vice President	1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Silvana Battaglia	officer: Executive Vice President	227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Walgreens Boots Alliance, Inc.	10 percent owner	108 WILMOT ROAD, DEERFIELD IL 60015
Gina Clark	officer: Executive Vice President	1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Werner Baumann	director	1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Lauren M Tyler	director	C/O ALLEGHANY CORPORATION, 1411 BROADWAY, 34TH FLOOR, NEW YORK NY 10018
Robert P. Mauch	officer: Executive Vice President	1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Redonda Miller	director	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Lorence H. Kim	director	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Walgreens Boots Alliance Holdings Llc	10 percent owner	108 WILMOT ROAD, DEERFIELD IL 60015
Lon R Greenberg	director	460 NORTH GULPH ROAD, KING OF PRUSSIA PA 19406
John G. Chou	officer: Executive Vice President	1300 MORRIS DRIVE, CHESTERBROOK PA 19087